Every Form 4 that AIM ImmunoTech Inc. (AIM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AIM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIM filings page.
AIM ImmunoTech Inc. (AIM) reported that CEO and President Thomas K. Equels purchased 24,000 shares of common stock in a open market or private transaction on September 17, 2026, at $0.208 per share, bringing his directly held position to 126,822 shares.
No Rule 10b5-1 trading plan is reported for this transaction.
AIM ImmunoTech Inc. (AIM) reported that its CEO and President, Thomas K. Equels, purchased 11,000 shares of common stock on September 16, 2026, in an open-market or private transaction at $0.21 per share. Following this buy, he directly holds 102,822 common shares, and no Rule 10b5-1 trading plan is reported.
AIM ImmunoTech Inc. (AIM) reported that CEO & President Thomas K. Equels purchased 22,000 shares of its Common Stock on September 15, 2026 in a purchase described as an open market or private transaction at $0.221 per share. Following this buy, he directly owns 91,822 shares of AIM Common Stock. No Rule 10b5-1 trading plan is reported for this transaction.
AIM ImmunoTech Inc. (AIM) reported that CEO and President Thomas K. Equels purchased 5,900 shares of its Common Stock on September 14, 2026, in a purchase characterized as an open market or private transaction at $0.219 per share. Following this transaction, he holds 69,822 shares with direct ownership, and no Rule 10b5-1 trading plan is reported.
AIM ImmunoTech Inc. CEO and President Thomas K. Equels converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock. The preferred stock position was reduced to zero, and his directly held common stock increased to 63,922 shares following the transaction.
AIM ImmunoTech Inc. director David I. Chemerow converted preferred stock into common shares. He converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock through a derivative conversion at no stated cash price. A footnote explains each preferred share is convertible into 1,000 common shares, effectively valuing the conversion at $1.00 per common share. Following the conversion, he directly holds 28,441 shares of AIM ImmunoTech common stock, with no remaining Series G preferred shares reported.
AIM ImmunoTech Inc. CEO and President Thomas K. Equels reported changes in his holdings of derivative securities related to a rights offering. On March 6, 2026, he held 25 shares of Series G Convertible Preferred Stock, each with a stated value of $1,000 and convertible into 1,000 shares of common stock, issued as part of a subscription right in a rights offering. He also reported 50,000 Class G Warrants, each exercisable for one share of common stock at an exercise price of $1.00 per share, likewise issued as part of a subscription right in a rights offering. Following these transactions, he directly held 38,922 shares of common stock.
AIM ImmunoTech director David I. Chemerow reported new derivative holdings tied to a rights offering. He now holds 25 shares of Series G Convertible Preferred Stock, each with a stated value of $1,000 and convertible into 1,000 shares of common stock, issued through a subscription right in a rights offering.
He also reported 50,000 Class G Warrants, each exercisable for one share of common stock at an exercise price of $1.00, likewise issued as part of a subscription right in a rights offering. Following these transactions, he directly holds 3,441 shares of common stock, alongside the preferred shares and warrants.
ImmunoTech Inc. director David I. Chemerow reported an indirect acquisition of common stock through The David I Chemerow 1992 Trust. On 02/05/2026, the trust acquired 2,800 shares of ImmunoTech common stock at a price of $1.23 per share.
Following this transaction, the trust beneficially owned a total of 3,441 ImmunoTech common shares, all reported as indirectly held on behalf of Chemerow.